Biden Administration Initiates Drug Price Negotiations for Medicare Cost Reduction

By IndraStra Global News Team

Cover Image Attribute: Image by Pexels from Pixabay

The Biden administration has embarked on a pioneering path to curb escalating Medicare expenditures by identifying ten drugs, including Eliquis, a blood thinner, and well-known diabetes treatments like Jardiance, for direct price negotiations with manufacturers. This unprecedented initiative seeks to alleviate costs for patients while grappling with potential legal challenges from pharmaceutical companies and stern opposition from Republican lawmakers. The move forms a pivotal element of President Joe Biden's reelection strategy, as he spotlights his efforts to mitigate the financial burdens faced by Americans in the face of inflationary pressures.
Aiming to address the pressing issue of mounting healthcare costs, the administration disclosed the list of drugs for negotiation on Tuesday. These medicines, among them Eliquis, a blood clot treatment manufactured by Bristol Myers Squibb and Pfizer, and diabetes medications like Jardiance from Eli Lilly and Co., are collectively responsible for over $50 billion in Medicare prescription drug expenses spanning June 1, 2022, to May 31.
The unprecedented Inflation Reduction Act, signed by Biden last year, is the driving force behind this decisive step. The legislation mandates direct price negotiations between the federal government and pharmaceutical companies regarding the prices of certain high-cost drugs within Medicare.
Speaking about the initiative, Biden stated, "For many Americans, the cost of one drug is the difference between life and death, dignity and dependence, hope and fear. That is why we will continue the fight to lower healthcare costs — and we will not stop until we finish the job."
The drive to negotiate prices is intended to benefit patients who are burdened with high deductibles even while they have coverage. Currently, pharmacy benefit managers overseeing Medicare prescription plans negotiate rebates on drug prices. Although these rebates sometimes contribute to reducing premiums for coverage, they often do not alter the expenses incurred by patients at the pharmacy counter.
The pharmaceutical industry, aware of these impending rules for months, has braced itself for a legal battle. The plan is already facing several lawsuits, with major pharmaceutical companies like Merck and Bristol-Myers Squibb challenging the initiative. Additionally, the Pharmaceutical Research and Manufacturers of America (PhRMA), a prominent lobbying group, has expressed concerns about government intervention in pricing decisions.
PhRMA's complaint contends that the act compels drugmakers to accept a "government-dictated price" under the threat of substantial taxation. The organization also raises apprehensions regarding the excessive authority given to the U.S. Department of Health and Human Services in setting prices.
Republican lawmakers, too, have vehemently criticized the administration's approach. They are apprehensive that the initiative might discourage the introduction of new drugs susceptible to future negotiations and have questioned the government's competence to determine drug prices.
The Centers for Medicare and Medicaid Services (CMS) plans to embark on negotiations for drugs that account for the highest expenditure. These drugs must lack generic counterparts and must have received approval from the Food and Drug Administration (FDA). CMS is set to convene meetings with the manufacturers featured on the list this fall and intends to engage in patient-centric listening sessions.
By February 2024, the government will present its initial offer for a maximum fair price and will subsequently grant drugmakers an opportunity to respond. Implementation of negotiated prices is anticipated by 2026. It is plausible that additional drugs may be included in the program in the coming years as this endeavor takes strides toward reshaping the landscape of drug pricing and healthcare affordability.

IndraStra Global is now available on
Apple News, Google News, Flipboard, RSS, and Telegram

COPYRIGHT: This article is published under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. https://creativecommons.org/licenses/by-nc-nd/4.0/

REPUBLISH: Republish our articles online or in print for free if you follow these guidelines. https://www.indrastra.com/p/republish-us.html